First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
Inhaled Azacitidine
Lung cancer
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
07
01
2021
revised:
02
02
2021
accepted:
12
02
2021
pubmed:
27
2
2021
medline:
22
6
2021
entrez:
26
2
2021
Statut:
ppublish
Résumé
Aerosolized Azacitidine has been shown to inhibit orthotopic lung cancer growth and induce re-expression of methylated tumor suppressor genes in murine models. We hypothesized that inhaled Azacitidine is safe and effective in reversing epigenetic changes in the bronchial epithelium secondary to chronic smoking. We report the first in human study of inhaled Azacitidine. Azacitidine in aqueous solution was used to generate an aerosol suspension of 0.25-5 μm particle size. Main inclusion criteria: Stage IV or recurrent NSCLC with predominantly lung involvement, ≥1 prior systemic therapy, ECOG PS 0-1, and adequate pulmonary function. Patients received inhaled Azacitidine daily on days 1-5 and 15-19 of 28-day cycles, at 3 escalating doses (15, 30 and 45 mg/m From 3/2015 to 2/2018, eight patients received a median number of 2 (IQR = 1) cycles of inhaled Azacitidine. No clinically significant adverse events were observed, except one patient treated at the highest dose developed an asymptomatic grade 2 decreased DLCO which resolved spontaneously. One patient receiving 12 cycles of therapy had an objective and durable partial response, and two patients had stable disease. Plasma Azacitidine was only briefly detectable in patients treated at the higher doses. Moreover, in 2 of 3 participants who agreed and underwent pre- and post-treatment bronchoscopy, the global DNA methylation in the bronchial epithelium decreased by 24 % and 79 % post-therapy, respectively. The interval between last inhaled treatment and bronchoscopy was 3 days. Inhaled Azacitidine resulted in negligible plasma levels compared to the previously reported subcutaneous administration and was well-tolerated. The results justify the continued development of inhaled Azacitidine at non-cytotoxic doses for patients with lung-confined malignant and/or premalignant lesions.
Sections du résumé
BACKGROUND
Aerosolized Azacitidine has been shown to inhibit orthotopic lung cancer growth and induce re-expression of methylated tumor suppressor genes in murine models. We hypothesized that inhaled Azacitidine is safe and effective in reversing epigenetic changes in the bronchial epithelium secondary to chronic smoking.
PATIENTS AND METHODS
We report the first in human study of inhaled Azacitidine. Azacitidine in aqueous solution was used to generate an aerosol suspension of 0.25-5 μm particle size. Main inclusion criteria: Stage IV or recurrent NSCLC with predominantly lung involvement, ≥1 prior systemic therapy, ECOG PS 0-1, and adequate pulmonary function. Patients received inhaled Azacitidine daily on days 1-5 and 15-19 of 28-day cycles, at 3 escalating doses (15, 30 and 45 mg/m
RESULTS
From 3/2015 to 2/2018, eight patients received a median number of 2 (IQR = 1) cycles of inhaled Azacitidine. No clinically significant adverse events were observed, except one patient treated at the highest dose developed an asymptomatic grade 2 decreased DLCO which resolved spontaneously. One patient receiving 12 cycles of therapy had an objective and durable partial response, and two patients had stable disease. Plasma Azacitidine was only briefly detectable in patients treated at the higher doses. Moreover, in 2 of 3 participants who agreed and underwent pre- and post-treatment bronchoscopy, the global DNA methylation in the bronchial epithelium decreased by 24 % and 79 % post-therapy, respectively. The interval between last inhaled treatment and bronchoscopy was 3 days.
CONCLUSIONS
Inhaled Azacitidine resulted in negligible plasma levels compared to the previously reported subcutaneous administration and was well-tolerated. The results justify the continued development of inhaled Azacitidine at non-cytotoxic doses for patients with lung-confined malignant and/or premalignant lesions.
Identifiants
pubmed: 33636454
pii: S0169-5002(21)00075-1
doi: 10.1016/j.lungcan.2021.02.015
pmc: PMC8026712
mid: NIHMS1677068
pii:
doi:
Substances chimiques
Azacitidine
M801H13NRU
Banques de données
ClinicalTrials.gov
['NCT02009436']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
99-104Subventions
Organisme : NCI NIH HHS
ID : R01 CA154755
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
J Toxicol Environ Health A. 2017;80(23-24):1321-1330
pubmed: 29048996
Front Oncol. 2013 Jul 29;3:188
pubmed: 23908969
Br J Clin Pharmacol. 2003 Dec;56(6):588-99
pubmed: 14616418
Br J Cancer. 2020 Apr;122(8):1194-1204
pubmed: 32103148
Biomarkers. 2016 Nov;21(7):589-99
pubmed: 27122255
Cancer Res. 2016 Aug 15;76(16):4741-51
pubmed: 27302168
Lancet Diabetes Endocrinol. 2015 Nov;3(11):886-94
pubmed: 26341170
PLoS One. 2014 Oct 27;9(10):e109874
pubmed: 25347303
Eur J Cancer. 2019 Feb;108:120-128
pubmed: 30654297
Hum Mol Genet. 2017 Aug 1;26(15):3014-3027
pubmed: 28854564
Int J Cancer. 2014 Jul 15;135(2):319-34
pubmed: 24921089
Mol Biol Rep. 2013 Jan;40(1):309-25
pubmed: 23086271
Cancers (Basel). 2020 May 17;12(5):
pubmed: 32429547
Tob Induc Dis. 2014 Sep 05;12(1):15
pubmed: 25214829
Leukemia. 2008 Sep;22(9):1680-4
pubmed: 18548103
Clin Lung Cancer. 2016 May;17(3):214-222.e1
pubmed: 26531130
Clin Epigenetics. 2019 Dec 4;11(1):182
pubmed: 31801617
Clin Cancer Res. 2007 Apr 15;13(8):2414-21
pubmed: 17438100
Clin Lung Cancer. 2010 Nov 1;11(6):405-11
pubmed: 21062731
Clin Cancer Res. 2006 Oct 1;12(19):5777-85
pubmed: 17020984